Amyris Inc (NASDAQ:AMRS) saw unusually large options trading activity on Wednesday. Traders purchased 813 call options on the company. This represents an increase of 1,406% compared to the typical daily volume of 54 call options.
Large investors have recently modified their holdings of the stock. Tanaka Capital Management Inc. lifted its position in Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 221,295 shares during the last quarter. KBC Group NV lifted its position in Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 41,834 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 4,603 shares during the last quarter. Finally, Carl Domino Inc bought a new stake in Amyris in the 3rd quarter valued at about $182,000. Hedge funds and other institutional investors own 22.84% of the company’s stock.
AMRS has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Wednesday, October 4th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Amyris in a research report on Tuesday, September 26th. Cowen restated a “hold” rating and issued a $4.00 price target on shares of Amyris in a research report on Wednesday, November 29th. Finally, ValuEngine downgraded shares of Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.04). The company had revenue of $24.20 million for the quarter, compared to analysts’ expectations of $36.30 million. The firm’s revenue was down 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.07) EPS. equities analysts predict that Amyris will post -3.32 earnings per share for the current year.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.